Pharmaceutical composition containing two active ingredients for smoking cessation
AssigneePeirce Management, LLC
InventorsMark Hirsh, Kamal K. Midha, Hans E. Junginger
Life of this patent
Estimating the term…
Abstract
A kit to alleviate tobacco-smoking withdrawal symptoms in a patient is disclosed which comprises: (a) a therapeutically effective amount of nicotine, at least one active nicotine metabolite, a combination of nicotine and an active nicotine metabolite, or an azapirone, or a pharmaceutically acceptable salt thereof; (b) a transdermal delivery system consisting essentially of a bupropion base in a therapeutically effective amount; and (c) a packaging material surrounding (a) and (b).
Claims22
A pharmaceutical composition in unit dosage form to alleviate tobacco-smoking withdrawal symptoms which consists essentially of:
- (a) a therapeutically effective amount of nicotine, at least one active nicotine metabolite, a combination of nicotine and an active nicotine metabolite, or an azapirone, or a pharmaceutically acceptable salt thereof;
- and
- (b) a transdermal delivery system comprising bupropion base in a therapeutically effective amount.
A method of alleviating tobacco-smoking withdrawal symptoms in a patient who is refraining from smoking tobacco which comprises the step of administering to said patient a therapeutically effective amount of a pharmaceutical composition in unit dosage form to alleviate tobacco-smoking withdrawal symptoms which consists essentially of:
- (a) a therapeutically effective amount of nicotine, at least one active nicotine metabolite, a combination of nicotine and an active nicotine metabolite, or an azapirone, or a pharmaceutically acceptable salt thereof;
- and
- (b) a transdermal delivery system comprising bupropion base in a therapeutically effective amount.
A kit to alleviate tobacco-smoking withdrawal symptoms in a patient which consists essentially of:
- (a) a therapeutically effective amount of nicotine, at least one active nicotine metabolite, a combination of nicotine and an active nicotine metabolite, or an azapirone, or a pharmaceutically acceptable salt thereof;
- (b) a transdermal delivery system comprising bupropion base in a therapeutically effective amount;
- and
- (c) a packaging material surrounding (a) and (b).
Dependencies are inferred from the claim text.